Cargando…

p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma

We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinom...

Descripción completa

Detalles Bibliográficos
Autor principal: Shimada, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036386/
https://www.ncbi.nlm.nih.gov/pubmed/30003189
http://dx.doi.org/10.1002/ags3.12179
_version_ 1783338157813530624
author Shimada, Hideaki
author_facet Shimada, Hideaki
author_sort Shimada, Hideaki
collection PubMed
description We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV‐p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviral‐mediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV‐p53 were observed in these patients. One patient survived for over 5 years after the start of p53 gene therapy. Intratumoral injection of Ad5CMV‐p53 is therefore safe, feasible, and biologically active when given in multiple doses to patients with esophageal squamous cell carcinoma. Our observations from these clinical studies indicate that p53 is a useful molecular target both in the diagnosis and in the treatment of esophageal squamous cell carcinoma.
format Online
Article
Text
id pubmed-6036386
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60363862018-07-12 p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma Shimada, Hideaki Ann Gastroenterol Surg Review Articles We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV‐p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviral‐mediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV‐p53 were observed in these patients. One patient survived for over 5 years after the start of p53 gene therapy. Intratumoral injection of Ad5CMV‐p53 is therefore safe, feasible, and biologically active when given in multiple doses to patients with esophageal squamous cell carcinoma. Our observations from these clinical studies indicate that p53 is a useful molecular target both in the diagnosis and in the treatment of esophageal squamous cell carcinoma. John Wiley and Sons Inc. 2018-06-13 /pmc/articles/PMC6036386/ /pubmed/30003189 http://dx.doi.org/10.1002/ags3.12179 Text en © 2018 The Author. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Shimada, Hideaki
p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title_full p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title_fullStr p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title_full_unstemmed p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title_short p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
title_sort p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036386/
https://www.ncbi.nlm.nih.gov/pubmed/30003189
http://dx.doi.org/10.1002/ags3.12179
work_keys_str_mv AT shimadahideaki p53molecularapproachtodiagnosisandtreatmentofesophagealsquamouscellcarcinoma